河北医学2024，Vol.30Issue(11)：1918-1924,7.DOI:10.3969/j.issn.1006-6233.2024.11.031
益生菌在卡培他滨联合吡咯替尼治疗晚期乳腺癌中的作用探讨
The Effect of Probiotics on the Efficacy and Adverse Reactions of Breast Cancer Chemotherapy Combined with Targeted Therapy
摘要
Abstract
Objective:To explore the clinical efficacy and adverse reactions of probiotic combination with pyrotinib and capecitabine for the treatment of HER-2 positive advanced breast cancer,with a view to providing a reference for clinical treatment plans.Methods:One hundred and five HER-2 positive breast cancer patients were selected from January 2019 to August 2023 in the Affiliated Tumor Hospital of Guangxi Medical University and were divided into the study group and the control group by randomized numerical table method,and the numbers of cases were 53 and 52,respectively.The study group was treated with probiotics+pyrotinib+capecitabine,and the control group was treated with pyrotinib+capecitabine.The two groups were compared in terms of recent efficacy,the number of major intestinal flora colonies before and after chem-otherapy,T-lymphocyte subsets(CD3+,CD4+,CD4+/CD8+),inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),and tumor cell necrosis factor-alpha(TNF-alpha)〛,and the degree of cancer-caused fatigue[Piper Fatigue Scale(PFS)score],sleep quality[Pittsburgh Sleep Quality Index(PSQI)score],quality of life[European Organization for Research and Treatment of Cancer Quality of Life question-maire core 30(EORTC QLQ-C30)score],and adverse effects.Results:The total remission rate of the two groups was not statistically significant(P>0.05),but the rate of discontinuing or lowering the dose of pyrotin-ib due to adverse reactions was lower in the study group than in the control group(P<0.05);the number of bifidobacteria and Lactobacillus colonization was higher than that of the control group,and the number of Escherichia coli and enterococci colonization was lower than that of the control group after 2 cycles of treatment in the study group,and 4 cycles later(P<0.05);the number of peripheral blood CDs was higher than that of the control group after 2 cycles of treatment in the study group.After 2 cycles of treatment,peripheral blood CD3+,CD4+,CD4+/CD8+levels were higher than those of the control group(P<0.05);serum IL-6,IL-8,TNF-α levels were lower than those of the control group after 2 cycles of treatment and after 4 cycles of treat-ment in the study group(P<0.05);PFS and PSQI scores were lower than those of the control group after 2 cycles of chemotherapy and after 4 cycles of chemotherapy in the study group,and EORTC QLQ-C30 score was higher than that of the control group(P<0.05);the incidence of diarrhea in the study group was lower than that of the control group(P<0.05),and the difference in the incidence of hand-foot syndrome,leuko-penia,neutropenia,and thrombocytopenia was not statistically significant when compared with that of the con-trol group(P>0.05).Conclusion:Probiotic can promote the improvement of immune function in HER-2 positive breast cancer patients after treatment with pyrotinib combined with capecitabine,which can effectively reduce the occurrence of gastrointestinal-related adverse reactions,thus improving the quality of patient sur-vival.关键词
乳腺癌/益生菌/吡咯替尼/卡培他滨/免疫功能/生存质量Key words
Breast cancer/Probiotics/Pyrotinib/Capecitabine/Immune function/Survival quality引用本文复制引用
周文献,谭爱花,王洪学,贾昱娴,覃芳卉..益生菌在卡培他滨联合吡咯替尼治疗晚期乳腺癌中的作用探讨[J].河北医学,2024,30(11):1918-1924,7.基金项目
广西医疗卫生适宜技术开发与推广应用项目,(编号:S2021021) （编号:S2021021）
